Individual component analysis of gastrointestinal symptom rating scale for irritable bowel syndrome in irritable bowel syndrome patients treated with Bacillus coagulans SNZ 1969: additional findings from a randomized, double-blind, placebo-controlled study

Kishan P. V.; Raunak J. Soman; Dhruv Soman; Sarath Chandra Gorantla

doi:10.18203/2319-2003.ijbcp20250491

Authors

Kishan P. V. Sanzyme Biologics Pvt. Ltd., Hyderabad, Telangana, India
Raunak J. Soman Sanzyme Biologics Pvt. Ltd., Hyderabad, Telangana, India
Dhruv Soman Sanzyme Biologics Pvt. Ltd., Hyderabad, Telangana, India
Sarath Chandra Gorantla Department of Medical Gastroenterology, Apollo Hospitals, Jubilee Hills, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20250491

Keywords:

Bacillus coagulans SNZ 1969, Gastrointestinal symptom rating scale for irritable bowel syndrome, Irritable bowel syndrome, Probiotics

Abstract

This study evaluated the therapeutic efficacy of Bacillus coagulans SNZ 1969 (B. coagulans SNZ 1969) in patients with constipation-predominant irritable bowel syndrome (IBS-C) and diarrhea-predominant IBS (IBS-D). We conducted a randomized, double-blind, placebo-controlled trial in 80 patients (40 IBS-C, 40 IBS-D) who received either B. coagulans SNZ 1969 (500 million CFU) or placebo twice daily for 60 days. Assessments were performed at baseline and on days 30, 60, and 75. Here we present the additional findings of the individual components of Gastrointestinal Symptom Rating Scale for IBS (GSRS-IBS). Results demonstrated significant reductions in all individual components of GSRS-IBS (abdominal pain, bloating, constipation, diarrhea, and satiety) in both IBS-C and IBS-D patients treated with B. coagulans SNZ 1969 compared to placebo. In conclusion, B. coagulans SNZ 1969 found to be an effective therapeutic option for IBS, demonstrating broad efficacy across multiple symptom domains.

Metrics

Metrics Loading ...

References

Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. DOI: https://doi.org/10.2147/CLEP.S40245

Soman RJ, Gorantla SC, Swamy MV. Evaluation of efficacy and safety of Bacillus coagulans SNZ 1969 supplementation for irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Int J Basic Clin Pharmacol. 2022;11(6):550-58. DOI: https://doi.org/10.18203/2319-2003.ijbcp20222353

Chen M, Yuan L, Xie CR, Xiao-Ying W, Si-Jia F, Xin-Yu X, et al. Probiotics for the management of irritable bowel syndrome: a systematic review and three-level meta-analysis. Int J Surg. 2023;109(11):3631-47. DOI: https://doi.org/10.1097/JS9.0000000000000658

Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care. 2011;14(6):581-7. DOI: https://doi.org/10.1097/MCO.0b013e32834b8082

Ford AC, Quigley EM, Lacy BE, Anthony JL, Yuri AS, Lawrence RS, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-61. DOI: https://doi.org/10.1038/ajg.2014.202

Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-24. DOI: https://doi.org/10.3810/pgm.2009.03.1984

Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res. 2018;15:21. DOI: https://doi.org/10.29219/fnr.v62.1218

Majeed M, Nagabhushanam K, Natarajan S, Arumugam S, Furqan A, Anurag P, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21. DOI: https://doi.org/10.1186/s12937-016-0140-6

Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769-76. DOI: https://doi.org/10.3945/jn.110.135657

Majeed M, Nagabhushanam K, Paulose S, Arumugam S, Mundkur L. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. Medicine. 2023;102(9):e33109. DOI: https://doi.org/10.1097/MD.0000000000033109

Penet C, Kramer R, Parker J, Guthrie N. A randomized, double-blind, placebo-controlled, parallel study evaluating the efficacy of Bacillus subtilis MB40 to reduce abdominal discomfort, gas, and bloating. Alternat Therap Health Med. 2021;27:146-57.

Garvey SM, Mah E, Blonquist TM, Kaden VN, Spears JL. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: A randomized, double-blind, placebo-controlled trial. Gut Microbes. 2022;14(1):2122668. DOI: https://doi.org/10.1080/19490976.2022.2122668

Kang S, Park MY, Brooks I, Jaekyung L, Kim SH, Kim JY, et al. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: a randomized controlled trial. Food Res Int. 2021;146:110428. DOI: https://doi.org/10.1016/j.foodres.2021.110428

Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014;7(3):156.

Kim HJ, Cha RR, Kim HJ. Understanding the Rome IV: Irritable bowel syndrome and functional diarrhea. Kor J Med. 2017;92(4):366-71. DOI: https://doi.org/10.3904/kjm.2017.92.4.366

Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021;160(5):1486-501. DOI: https://doi.org/10.1053/j.gastro.2020.10.066